CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	0.55	10.06	5	14.04	7.24
Cash & Cash Equivalents	0.55	10.06	5	14.04	7.24
Cash Growth	-94.54%	100.93%	-64.35%	93.88%	1204.42%
Other Current Assets	1.04	2.51	2.47	1.46	0.65
Total Current Assets	1.59	12.56	7.48	15.5	7.89
Property, Plant & Equipment	0	0.01	0.02	0.02	0.02
Other Long-Term Assets	0.1	0.48	1.26	0.33	0
Total Long-Term Assets	0.11	0.49	1.28	0.36	0.02
Total Assets	1.7	13.05	8.76	15.85	7.91
Accounts Payable	5.83	4.51	1.98	0.95	0.29
Current Debt	0.3	0.41	0.39	0.44	0
Other Current Liabilities	0	0	0.22	0.52	0.02
Total Current Liabilities	6.13	4.92	2.59	1.91	0.31
Total Liabilities	6.13	4.92	2.59	1.91	0.31
Total Debt	0.3	0.41	0.39	0.44	0
Debt Growth	-26.63%	5.72%	-11.72%	-	-
Retained Earnings	-69.57	-50.72	-35.44	-20.95	-11.49
Shareholders' Equity	-4.43	8.13	6.16	13.95	7.6
Net Cash / Debt	0.25	9.65	4.62	13.6	7.24
Net Cash / Debt Growth	-97.43%	108.92%	-66.05%	87.81%	2939.81%
Net Cash Per Share	3.29	354.16	262.78	1227.57	795.83
Working Capital	-4.54	7.64	4.88	13.59	7.58
Book Value Per Share	-58.82	298.62	350.80	1258.97	835.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).